Your browser doesn't support javascript.
loading
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.
Xiang, Yuchu; Liu, Xudong; Wang, Yifan; Zheng, Dawei; Meng, Qiuxing; Jiang, Lingling; Yang, Sha; Zhang, Sijia; Zhang, Xin; Liu, Yan; Wang, Bo.
Afiliação
  • Xiang Y; West China Hospital of Sichuan University, Sichuan University, Chengdu, China.
  • Liu X; Institute of Medical Microbiology and Hygiene, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Wang Y; College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China.
  • Zheng D; State Key Laboratory for Oncogenes and Related Genes, Division of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Cancer Institute, Shanghai, China.
  • Meng Q; The College of Life Science, Sichuan University, Chengdu, China.
  • Jiang L; Department of Laboratory Medicine, Liuzhou People's Hospital, Liuzhou, China.
  • Yang S; Guangxi Health Commission Key Laboratory of Clinical Biotechnology (Liuzhou People's Hospital), Liuzhou, China.
  • Zhang S; Guangxi Medical University Cancer Hospital, Nanning, China.
  • Zhang X; Institute of Pharmaceutical Science, China Pharmaceutical University, Nanjing, China.
  • Liu Y; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang B; Zhongshan Hospital of Fudan University, Xiamen, Fujian, China.
Front Immunol ; 15: 1366260, 2024.
Article em En | MEDLINE | ID: mdl-38655260
ABSTRACT
Resistance to targeted therapy and immunotherapy in non-small cell lung cancer (NSCLC) is a significant challenge in the treatment of this disease. The mechanisms of resistance are multifactorial and include molecular target alterations and activation of alternative pathways, tumor heterogeneity and tumor microenvironment change, immune evasion, and immunosuppression. Promising strategies for overcoming resistance include the development of combination therapies, understanding the resistance mechanisms to better use novel drug targets, the identification of biomarkers, the modulation of the tumor microenvironment and so on. Ongoing research into the mechanisms of resistance and the development of new therapeutic approaches hold great promise for improving outcomes for patients with NSCLC. Here, we summarize diverse mechanisms driving resistance to targeted therapy and immunotherapy in NSCLC and the latest potential and promising strategies to overcome the resistance to help patients who suffer from NSCLC.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Terapia de Alvo Molecular / Microambiente Tumoral / Imunoterapia / Neoplasias Pulmonares Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Terapia de Alvo Molecular / Microambiente Tumoral / Imunoterapia / Neoplasias Pulmonares Limite: Animals / Humans Idioma: En Revista: Front Immunol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China